TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
Brief Summary: This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.


Options:
A: Arm Label: Paliperidone palmitate 3-month (PP3M); Type: EXPERIMENTAL; Interventions: Drug: PP3M 175 mg eq., Drug: PP3M 263 mg eq., Drug: PP3M 350 mg eq., Drug: PP3M 525 mg eq. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (20% Intralipid emulsion) | Intervention Type: DRUG; Name: PP3M 175 mg eq.; Assigned to Arm(s): Paliperidone palmitate 3-month (PP3M) | Intervention Type: DRUG; Name: PP3M 263 mg eq.; Assigned to Arm(s): Paliperidone palmitate 3-month (PP3M) | Intervention Type: DRUG; Name: PP3M 350 mg eq.; Assigned to Arm(s): Paliperidone palmitate 3-month (PP3M) | Intervention Type: DRUG; Name: PP3M 525 mg eq.; Assigned to Arm(s): Paliperidone palmitate 3-month (PP3M) | Intervention Type: DRUG; Name: Placebo (20% Intralipid emulsion); Assigned to Arm(s): Placebo
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 003
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole (OPC-34712); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole (OPC-34712) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
Brief Summary: This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.


Options:
A: Intervention Type: DRUG; Name: risperidone, quetiapine; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
C: Arm Label: ITI-007 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007, Drug: Placebo | Arm Label: ITI-007 High Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: ITI-007; Assigned to Arm(s): ITI-007 High Dose, ITI-007 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ITI-007 Low Dose, Placebo | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
D: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.
Brief Summary: The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung fibrosis. Patients living with pulmonary hypertension associated with interstitial lung disease have a risk of increased number of hospitalisations because of worsening of their condition. Until now there is no approved medication for this disease. The current treatment of pulmonary hypertension associated with interstitial lung disease consists: of oxygen and medical treatment with vasodilators, e.g. so-called Calcium-antagonists. Therefore, there is a need for new drugs in the treatment of pulmonary hypertension associated with interstitial lung disease.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
B: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 1
D: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521), Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Sildenafil | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Brief Summary: The aim of this study is to investigate the efficacy of neuroscience-guided computerized cognitive training exercises on the remediation of cognitive deficits and symptoms associated with recent-onset schizophrenia and to examine the influence of subject characteristics, brain structure and function, and pharmacotherapy on the response to remediation.


Options:
A: Arm Label: Cognitive Remediation; Type: EXPERIMENTAL; Interventions: Drug: Cognitive Remediation | Arm Label: Cognitive activity control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cognitive Remediation; Assigned to Arm(s): Cognitive Remediation
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): 1
C: Arm Label: Posit Science Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Targeted cognitive training, Behavioral: Bridging groups | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer control, Behavioral: Health and wellness groups | Intervention Type: BEHAVIORAL; Name: Targeted cognitive training; Assigned to Arm(s): Posit Science Intervention | Intervention Type: BEHAVIORAL; Name: Computer control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Bridging groups; Assigned to Arm(s): Posit Science Intervention | Intervention Type: BEHAVIORAL; Name: Health and wellness groups; Assigned to Arm(s): Control
D: Arm Label: Targeted Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Targeted Cognitive Training | Arm Label: Social Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Social Cognitive Training | Intervention Type: OTHER; Name: Targeted Cognitive Training; Assigned to Arm(s): Targeted Cognitive Training | Intervention Type: OTHER; Name: Social Cognitive Training; Assigned to Arm(s): Social Cognitive Training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Brief Summary: The aim of this study is to investigate the efficacy of neuroscience-guided computerized cognitive training exercises on the remediation of cognitive deficits and symptoms associated with recent-onset schizophrenia and to examine the influence of subject characteristics, brain structure and function, and pharmacotherapy on the response to remediation.


Options:
A: Arm Label: Glycine; Type: EXPERIMENTAL; Interventions: Drug: Glycine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycine; Assigned to Arm(s): Glycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): 1
C: Arm Label: Standard treatment + cognitive remediation; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive remediation, Behavioral: Standard treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive remediation; Assigned to Arm(s): Standard treatment + cognitive remediation | Intervention Type: BEHAVIORAL; Name: Standard treatment; Assigned to Arm(s): Standard treatment, Standard treatment + cognitive remediation
D: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare the efficacy and safety of titrated oral misoprostol solution with intravenous oxytocin for labor augmentation in women without adequate uterine contractions.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
B: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
D: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare the efficacy and safety of titrated oral misoprostol solution with intravenous oxytocin for labor augmentation in women without adequate uterine contractions.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
C: Arm Label: Oxytocin augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Misoprostol augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol augmentation | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin augmentation
D: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DEMO II: A Randomized, Parallel-group, Observer-blinded Clinical Trial of Aerobic Exercise Versus Stretching Exercise for Patients With Light to Moderate Depression
Brief Summary: This trial investigates the biological effect of exercise training on depression. Participants will randomly be allocated to either a aerobic exercise group performing exercise on stationary bikes or a group performing low-impact exercise such as stretching exercises. Both groups will attend sessions three times per week for 3 months. Before and after the intervention the investigators will measure the severity of depression using the Hamilton depression rating scale (HAM-D17).


Options:
A: Arm Label: Individual Placement and Support-vocational rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support-vocational rehabilitation | Arm Label: Vocational rehabilitation available at study site; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vocational rehabilitation available | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support-vocational rehabilitation; Assigned to Arm(s): Individual Placement and Support-vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: Vocational rehabilitation available; Assigned to Arm(s): Vocational rehabilitation available at study site
B: Intervention Type: DRUG; Name: desvenlafaxine 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: desvenlafaxine 100 mg; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DEMO II: A Randomized, Parallel-group, Observer-blinded Clinical Trial of Aerobic Exercise Versus Stretching Exercise for Patients With Light to Moderate Depression
Brief Summary: This trial investigates the biological effect of exercise training on depression. Participants will randomly be allocated to either a aerobic exercise group performing exercise on stationary bikes or a group performing low-impact exercise such as stretching exercises. Both groups will attend sessions three times per week for 3 months. Before and after the intervention the investigators will measure the severity of depression using the Hamilton depression rating scale (HAM-D17).


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: Micronutrients | Arm Label: 3; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise, Dietary Supplement: Micronutrients | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Activities of daily living + placebo | Intervention Type: BEHAVIORAL; Name: Regular aerobic physical exercise; Assigned to Arm(s): 1, 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: Activities of daily living + placebo; Assigned to Arm(s): 4
B: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer
Brief Summary: The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).


Options:
A: Arm Label: open label; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): open label | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): open label
B: Arm Label: Lapatinib Oral Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Intervention Type: DRUG; Name: Oral lapatinib tablets or placebo tablets; Assigned to Arm(s): Lapatinib Oral Tablets, Placebo Control
C: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1

Answer: A